CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificates has been reported as lost by the shareholders of the company.07-07-2023
07-07-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificate has been reported as lost by the shareholder of the Company22-06-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificate has been reported as lost by the shareholder of the Company.12-06-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release regarding grant of United States Food and Drug Administration (USFDA) approval for the Abbreviated New Drug Application (ANDA) Cisatracurium Besylate Injection USP for our subsdiary Caplin Steriles Limited12-06-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned share certificate has been reported as lost by the shareholder of the Company.08-06-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
In continuation of our letter dated May 22, 2023 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the transcript of the presentation made on Saturday, May 27, 2023, on audited Financial Results (Consolidated and Standalone) of the Company for the quarter and year ended March 31, 2023, is available on the Company's website02-06-2023
Caplin Point chalks 350 crore capex for expansion
Caplin Point said the capex outlay includes expansion of Phase 2 & 3 projects of Caplin Steriles02-06-2023
USFDA issues four observations on Caplin Point subsidiary's injectable unit
The observations were followed by the US drug regulator's goods manufacturing practice (GMC) and pre-approval inspection (PAI) at Caplin Steriles' injectable site at Gummidipoondi01-06-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
US FDA inspection completed at Caplin Steriles Injectable site at Gummidipoondi01-06-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached the Annual Secretarial Compliance report for the year ended 31st March, 202329-05-2023